Clear market notes built around the JSE, the rand, and what matters locally.

2026-09-02 16:40 • The Motley Fool Mixed Axe Cap view: Selective

The Trade Desk stock surged 4.9% after the FTC and 22 states filed suit against Amazon for allegedly using deceptive ad pricing practices, including undisclosed surcharges. This legal action highlights The Trade Desk's competitive advantage through transparent pricing and could help the company recapture market share from competitors with closed ecosystems.

Axe note: The Trade Desk’s stock bounce on Amazon’s lawsuit highlights a US tech tussle with limited local impact.

2026-09-02 16:30 • The Motley Fool Positive Axe Cap view: Selective

Bristol Myers Squibb and Pfizer are recommended as undervalued pharmaceutical stocks offering above-average dividend yields. BMY offers a safer 3.76% yield with a sustainable 45% FCF payout ratio and growing oncology portfolio, while PFE provides a higher 6.04% yield but with a riskier 89% payout ratio. Both trade at steep discounts to peers despite facing patent expiration challenges.

Axe note: Bristol Myers Squibb and Pfizer look cheap in the US, but rand investors have better options locally and must watch FX risks.

2026-09-02 16:30 • The Motley Fool Positive Axe Cap view: Selective

Salesforce partnered with Anthropic to integrate Claude as the default AI reasoning engine across its products including Agentforce and Slack. The deal addresses investor concerns about AI disrupting Salesforce's business model while creating a powerful upsell opportunity, as AI features are exclusive to premium subscriptions. The stock surged 23% on the announcement, and Q2 results showed 11% revenue growth and 240% annualized growth for Agentforce to $1.5 billion.

Axe note: Salesforce’s deal with Anthropic eases AI disruption fears and paves the way for premium upsells.